SOD, POD and CAT activities under S treatment significantly decreased by 29.68%, 20.89% and 46.47%, respectively, compared with CK treatment, while under MS treatment, they significantly increased by 14.45%, 20.75% and 59.61% compared with S treatment (p < 0.05). This evidence concerns the gene SOD1 and myeloid sarcoma.